Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients

Saudi Medical Journal

Volumn 25, Issue 6, 2004, Pages 785-791

  Shaheen, Faisal A ^a   Akeel, Nabeela M ^a   Badawi, Laila S ^a   Souqiyyeh, Muhammad Z ^b  

^a KING FAHAD GENERAL HOSPITAL   (Saudi Arabia)

^b Saudi Center for Organ Transplantation   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM CARBONATE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D;

ADOLESCENT; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; INCIDENCE; KIDNEY FAILURE; MALE; PHOSPHATE BLOOD LEVEL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SAUDI ARABIA; SHORT COURSE THERAPY; TITRIMETRY;

ADULT; ANALYSIS OF VARIANCE; CALCIUM CARBONATE; CHI-SQUARE DISTRIBUTION; CROSS-OVER STUDIES; EPOXY COMPOUNDS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PHOSPHORUS METABOLISM DISORDERS; POLYAMINES; POLYETHYLENES; PROSPECTIVE STUDIES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 3042775140     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Chertow GM, Burke SK, Larazus JM, Stenzel KH, Wombolt D, Goldberg D, et al. Polyallylamine hydrochloride) (RensGc): a non-calcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997; 29: 66-71.
2. Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, et al. A comparison of the calcium-free phosphate binder Sevelamer Hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999; 33: 694-701.
3. Chertow GM, Dillon M, Burke SK, Steg M, Bleyer AJ, Garrett BN et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium: strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 1999; 51: 18-26.
4. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium phosphate product and lipid profile of hemodialysis patients. Nephrol Dial Transplant 2000; 15: 559.
5. Halevy D, Radhakrishnan J, Appel GB. Racial and socioeconomic factors in glomerular disease. Semin Nephrol 2001; 21: 403-410.
6. Magee MH. Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol 2001; 41: 1180-1194.
7. Kumar R. Calcium disorders. In: Kokko J, Tannen, editors. Fluids and Electrolytes. 3rd ed. Philadelphia (PA): WB Saunders Company; 1996. p. 391-419.
8. Hou SH, Zhao J, Ellman CF, Hu J, Griffin Z, Spiegel DM, et al. Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis 1991; 18: 217-224.
9. Salomon DR, Mitch WE. Therapy of disordered divalent ion metabolism in chronic renal failure. In: Brenner BM, Stein JH, editors. Contemporary Issues in Nephrology: Divalent Ion Homeostasis. New York (NY): Churchill Livingstone; 1983. p. 319-355.
10. Makoff DL, Gordon A, Franklin SS, Gerstein AR, Maxwell MH. Chronic calcium carbonate therapy in uremia. Arch Intern Med 1969; 123: 15-21.
11. Boyce BF, Fell GS, Elder HY, Junor BJ, Elliot HL, Beastall G, et al. Hypercalcaemic osteomalacia due to aluminium toxicity. Lancet 1982; 2: 1009-1013.
12. Emmett M, Sirmon MD, Kirkpatrick WG, Nolan CR, Schmitt GW, Cleveland MV. Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis 1991; 17: 544-550.
13. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard D. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989; 321: 274-279.
14. Kumar R. Calcium disorders. In: Kokko J, Tannen R, editors. Fluids and Electrolytes. 3rd ed. Philadelphia (PA): WB Saunders Company; 1996. p. 391-419.
15. Friedman SA, Novack S, Thomson GE. Arterial calcification and gangrene in uremia. N Engl J Med 1969; 280: 1392-1394.
16. Burke SL, Slatopolsky EA, Goldberg DI. Renagel, a novel calcium- and aluminum-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 1997; 12: 1640-1644.
17. Slatopolsky EA, Burke SK, Dillon MA, and the RenaGel Study Group. RenaGel: a nonabsorbed calcium-and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 1999; 55: 299-307.
18. Hervas JG, Prados D, Cerezo S. Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: A comparison with calcium acetate. Kidney Int Suppl 2003; 85: 69-72.
19. Sadek T, Mazouz H, Bahloul H, Oprisiu R, El-Esper N, El-Esper I, et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Nephrol Dial Transplant 2003; 18: 582-588.
20. Castro R, Herman A, Ferreira C, Travassos F, Nunes-Azevedo J, Oliveira M. RenaGel efficacy in severe secondary hyperparathyroidism. Nefrologia 2002; 22: 448-455.
21. McIntyre CW, Patel V, Taylor GS, Fluck RJ. A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic hemodialysis patients. Nephrol Dial Transplant 2002; 17: 1643-1648.
22. Gallieni M, Cozzolino M, Carpani P, Zoni U, Brancaccio D. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients. Nephrol 2001; 14: 176-183.
23. Nagano N, Miyata S, Obana S, Ozai M, Kobayashi N, Fukushima N, et al. Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant 2001; 16: 1870-1878.
24. Salem MM. Hyperparathyroidism in the hemodialysis population: A survey of 612 patients. Am J Kidney Dis 1997; 29: 862-865.
25. Meric F, Yap P, Bia MJ. Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy. Am J Kidney Dis 1990; 5: 459-464.
26. Felsenfield AJ, Llach F. Parathyroid gland function in chronic renal failure. Kidney Int 1993; 43: 771-789.
27. Nagano N, Miyata S, Obana S, Kobayashi N, Abe M, Fukushima N, et al. Sevelamer hydrochloride, a calcium-free phosphate binder, inhibits parathyroid cell proliferation in partially nephrectomized rats. Nephrol Dial Transplant 2003; 18 Suppl 3: III81-III85.
28. Molgaard J, von Schenck H, Olsson AG. Comparative effects of simvastatin and cholestyramine in treatment of patients with hypercholesterolemia. Eur J Clin Pharmacol 1989; 36: 455-460.
29. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364.
30. Bommer J, Strohbeck E, Goerich J, Balmer M, Zuna I. Arteriosclerosis in dialysis patients. Int J Artif Organs 1996; 19: 638-640.
31. U.S. Renal Data System (USRDS). Annual Data Report: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda (MD): USRDS; 1997. p. 93.
32. Scandinavian Simvastatin Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
33. The Lovastatin Study Group III. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. JAMA 1988; 260: 359-366.
34. Nakagawa K. A study of aortic calcification in uremia. Nippon Jinzo Gakkai Shi. Japanese Journal of Nephrology 1997; 39: 135-143.
35. Katz AI, Hampers CL, Merrill JP. Secondary hyper parathyroidism and renal osteodystrophy in chronic renal failure. Medicine 1969; 48: 333-377.
36. Detrano RC, Wong ND, Tang W, French WJ, Georgiou D, Young E, et al. Prognostic significance of cardiac cinefluoroscopy for coronary calcific deposits in asymptomatic high risk subjects. J Am Coll Cardiol 1994; 24: 354-358.
37. Wexler L, Brundage B, Crouse J, Detrano R, Fuster V, Maddahi J, et al. Coronary artery calcification: Pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professions from the American Heart Association. Circulation 1996; 94: 1175-1192.
38. Danielson R, Sigvaldason H, Thorgeirsson G, Sigfussion N. Predominance of aortic calcification as an atherosclerotic manifestation in women: The Reykjavik Study. J Clin Epidemiol 1996; 3: 383-387.
39. Tomson C. Vascular calcification in chronic renal failure. Nephron Clin Pract 2003; 93: 124-130.
40. Russell R, Brookshire MA, Zekonis M, Moe SM Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca × P product and aggressive wound care. Clin Nephrol 2002; 58: 238-243.
41. Cozzolino M, Dusso AS, Liapis H, Finch J, Lu Y, Burke SK et al. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. J Am Soc Nephrol 2002; 13: 2299-2308.
42. Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252.
43. Collins AJ, St Peter WL, Dalleska FW, Ebben JP, Ma JZ. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin Nephrol 2000; 54: 334-341.
44. Brophy DF, Wallace JF, Kennedy DT, Gehr TW, Holdford DA. Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia. Pharmacotherapy 2000; 20: 950-957.
45. Bleyer AJ. Phosphate binder usage in kidney failure patients. Expert Opin Pharmacother 2003; 4: 941-947.
46. Albaaj F, Hutchison A. Hyperphosphataemia in renal failure: causes, consequences and current management. Drugs 2003; 63: 577-596.
47. Cannata-Andia JB, Rodriguez-Garcia M. Hyperphosphataemia as a cardiovascular risk factor: How to manage the problem. Nephrol Dial Transplant 2002; 17 Suppl 11: 16-19.
48. Amin N. The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure. Nephrol Dial Transplant 2002; 17: 340-345.